Key Highlights
- Tempus AI has broadened its multi-year partnership with Gilead Sciences (GILD), enabling comprehensive access to its AI-powered Lens platform for oncology drug development.
- Gilead now has company-wide access to Tempus’ anonymized multimodal patient data spanning numerous cancer categories.
- Tempus’ Diagnostics division delivered 111.5% year-over-year revenue growth in 2025, with oncology testing volumes climbing 26%.
- The Data and Applications division generated $100.4M in Q4 2025 revenue, marking 25.1% YoY growth, while total remaining contract commitments exceeded $1.1 billion.
- TEM stock has climbed 17.9% in the past year, outperforming the medical information systems sector which declined 20%.
Tempus AI has announced an enhanced collaboration agreement with Gilead Sciences, significantly expanding upon an existing relationship that has been providing real-world oncology insights for Gilead’s drug development initiatives.
Under the upgraded agreement, Gilead gains organization-wide access to Tempus’ artificial intelligence-powered Lens platform. This provides comprehensive access to anonymized patient information across diverse cancer types, complemented by specialized analytical support from Tempus’ expert teams.
In the prior arrangement, Gilead utilized Tempus’ data resources for targeted applications including clinical trial planning, biomarker identification, therapeutic indication evaluation, and health outcome assessments. The current expansion significantly broadens this scope.
Patrick Loerch, Senior Vice President of Clinical Data Science at Gilead, described the collaboration as embodying their “shared priority of putting patients at the heart of innovation.” Ryan Fukushima, Chief Executive Officer of Tempus Data & Apps, emphasized that the enhanced access would provide AI-generated insights supporting Gilead’s research and development efforts. The companies did not reveal financial details of the arrangement.
Robust Diagnostic Performance Underpins Partnership
The partnership expansion arrives as Tempus delivers impressive diagnostic performance metrics.
Throughout 2025, Tempus‘ Diagnostics division achieved 111.5% revenue expansion compared to the previous year. Oncology test volume increased 26%, Hereditary testing grew 29%, and minimal residual disease (MRD) testing reached approximately 4,700 tests in Q4 alone—representing 56% sequential growth.
Company leadership projects oncology segment growth of approximately 30% in 2026, fueled by increased genomic sequencing adoption and broader MRD reimbursement availability.
The organization is also navigating regulatory pricing enhancements, transitioning its xT CDx test from a laboratory-developed format to FDA-approved status. The average selling price in Q4 2025 reached approximately $1,640, representing a $40 increase from Q3.
Data Operations Demonstrate Consistent Expansion
Tempus‘ Data and Applications division has emerged as a critical growth driver for the organization.
Q4 2025 revenues for this segment totaled $100.4 million, representing 25.1% year-over-year expansion. Net Revenue Retention measured 126%, demonstrating that current clients are increasing their spending. The company concluded 2025 with more than $1.1 billion in total remaining contract obligations.
Management forecasts approximately $1.59 billion in total 2026 revenues, suggesting roughly 25% growth.
Tempus is simultaneously developing advanced AI foundation models utilizing its proprietary datasets, with strategic plans extending beyond oncology into radiology, cardiovascular medicine, and neuropsychological applications.
The stock currently trades at a forward price-to-sales multiple of 5.02x, below the industry median of 5.38x.
Meanwhile, Gilead is pursuing an aggressive acquisition strategy. The pharmaceutical giant has revealed three transactions totaling approximately $15 billion, encompassing a $7.8 billion Arcellx acquisition and a $5 billion Tubulis purchase. Financial analysts at TD Cowen, BMO Capital, and Truist Securities maintain Buy or Outperform recommendations on Gilead with price targets spanning $155 to $174.
